Breaking News Instant updates and real-time market news.

IMGN

ImmunoGen

$2.72

-0.06 (-2.16%)

16:46
09/29/19
09/29
16:46
09/29/19
16:46

ImmunoGen reports 83% overall response rate for Phase 1b triplet cohort

ImmunoGen announced initial safety and overall response data from the Phase 1b FORWARD II triplet cohort evaluating mirvetuximab in combination with carboplatin and Avastin in patients with recurrent, platinum-sensitive ovarian cancer at the European Society for Medical Oncology 2019 Congress in Barcelona, Spain. In 41 patients with recurrent platinum-sensitive disease with medium or high folate receptor alpha expression levels who have received up to two prior lines of therapy, the confirmed overall response rate for the triplet was 83%, with a complete response rate of 17%. In a subset of 31 patients with only 1 prior line, the confirmed ORR was 90%, with a CR rate of 19%. These efficacy outcomes are encouraging relative to those reported in similar patient populations for other carboplatin and bevacizumab-based triplets. With a median follow up of 9.3 months, progression-free survival data are maturing. The combination of full dose mirvetuximab, carboplatin and bevacizumab is well tolerated. No new safety signals were seen; adverse events observed with the triplet were as expected based on the side effect profiles of each agent, with thrombocytopenia as the most common cause of drug-related discontinuations. Post-carboplatin, mirvetuximab and bevacizumab continuation/maintenance is well tolerated.

  • 29

    Sep

  • 30

    Sep

IMGN ImmunoGen
$2.72

-0.06 (-2.16%)

05/06/19
COWN
05/06/19
UPGRADE
COWN
Outperform
ImmunoGen upgraded to Outperform from Market Perform at Cowen
Cowen analyst Boris Peaker upgraded ImmunoGen to Outperform from Market Perform, saying the company noted on its Q1 earnings conference call that all secondary endpoints continued to trend positively in FRa high patients from the FORWARD I trial. Peaker tells investors in a research note that he sees additional clarity in the second half of the year after the company meets with the FDA, and says he believes shares are undervalued. If approved, Peaker says he believes that ImmunoGen's drug could acheive peak sales of ~1.6B per year.
05/06/19
05/06/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Sinclair Broadcast (SBGI) upgraded to Buy from Neutral at B. Riley FBR with analyst Barton Crockett saying yhe company's deal to acquire 21 regional sports networks from Disney (DIS) at valuation of $10.6B "looks like a home-run". 2. ImmunoGen (IMGN) upgraded to Buy from Neutral at H.C. Wainwright with analyst Debjit Chattopadhyay seeing 40% downside risk to the stock if the FDA does not consider mirvetuximab to be a clinically meaningful addition to the armametum against ovarian cancer versus a 145% upside potential. 3. Dish (DISH) upgraded to Neutral from Underperform at Credit Suisse with analyst Douglas Mitchelson saying he finds that risk/reward and potential catalysts across wireless and Pay TV are now in balance. 4. Post Holdings (POST) upgraded to Buy from Neutral at Goldman Sachs with analyst Jason English stating he views the recent pullback as a buying opportunity as he thinks transient headwinds were the reason results missed investor expectations in Q2. 5. Dentsply Sirona (XRAY) upgraded to Outperform from Market Perform at Barrington with analyst Michael Petusky saying the company's turnaround is "now on a firm, provable footing". This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/15/19
GUGG
05/15/19
DOWNGRADE
GUGG
Neutral
ImmunoGen downgraded to Neutral from Buy at Guggenheim
05/15/19
HCWC
05/15/19
NO CHANGE
Target $4
HCWC
Buy
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
H.C. Wainwright analyst Debjit Chattopadhyay said he had "misplaced optimism" about the path forward for ImmunoGen's mirvetuximab and admits to having been "wrong again" about the stock after the company disclosed that the FDA has recommended a new Phase 3 randomized trial to evaluate the safety and efficacy of mirvetuximab soravtansine in patients with high folate receptor alpha-positive, platinum-resistant ovarian cancer. The analyst believes the subsequent study, likely to be initiated during Q4, will likely mimic the FORWARD I Phase 3 program, but focus primarily on high FRalpha expressing patients. He "conservatively" assumes about 36 months from trial start to finish and now thinks potential commercialization won't come until the beginning of 2023. Chattopadhyay lowered his price target on ImmunoGen shares to $4 from $7 but keeps a Buy rating on the stock, which is down 31% to $2.19 in early trading.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/18/19
10/18
14:17
10/18/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/18/19
10/18
14:16
10/18/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$82.71

-1.42 (-1.69%)

14:15
10/18/19
10/18
14:15
10/18/19
14:15
Options
Diamondback Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

QQQ

Invesco QQQ Trust

$192.00

-1.56 (-0.81%)

, SPY

SPDR S&P 500 ETF Trust

$298.50

-0.74 (-0.25%)

14:13
10/18/19
10/18
14:13
10/18/19
14:13
Technical Analysis
On The Fly: ETF fund flow highlights »

For the week creations…

QQQ

Invesco QQQ Trust

$192.00

-1.56 (-0.81%)

SPY

SPDR S&P 500 ETF Trust

$298.50

-0.74 (-0.25%)

IWM

iShares Trust Russell 2000 Index Fund

$152.78

-0.56 (-0.37%)

XLU

Utilities SPDR

$63.76

0.16 (0.25%)

IVV

iShares Core S&P 500

$300.17

-0.76 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XEC

Cimarex Energy

$42.31

-0.36 (-0.84%)

14:05
10/18/19
10/18
14:05
10/18/19
14:05
Options
Cimarex Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

SPXC

SPX Corporation

$40.48

0.265 (0.66%)

13:58
10/18/19
10/18
13:58
10/18/19
13:58
Initiation
SPX Corporation initiated  »

SPX Corporation initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

WE

We Company

$0.00

(0.00%)

, JPM

JPMorgan

$120.80

0.41 (0.34%)

13:58
10/18/19
10/18
13:58
10/18/19
13:58
Periodicals
SoftBank, JPMorgan submit competing rescue packages for WeWork, FT says »

SoftBank (SFTBF) and…

WE

We Company

$0.00

(0.00%)

JPM

JPMorgan

$120.80

0.41 (0.34%)

SFTBF

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 27

    Oct

  • 04

    Nov

  • 21

    Nov

  • 14

    Jan

13:55
10/18/19
10/18
13:55
10/18/19
13:55
General news
Action Economics Survey results: »

Action Economics Survey…

JNJ

Johnson & Johnson

$129.11

-7.09 (-5.21%)

13:48
10/18/19
10/18
13:48
10/18/19
13:48
Recommendations
Johnson & Johnson analyst commentary  »

Credit Suisse says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 07

    Dec

DIS

Disney

$131.17

-1.2 (-0.91%)

, SNE

Sony

$58.86

-1.195 (-1.99%)

13:47
10/18/19
10/18
13:47
10/18/19
13:47
On The Fly
Box Office Battle: 'Maleficent,' 'Zombieland' sequels hit theaters »

Welcome to "Box Office…

DIS

Disney

$131.17

-1.2 (-0.91%)

SNE

Sony

$58.86

-1.195 (-1.99%)

T

AT&T

$38.09

0.27 (0.71%)

VIA

Viacom

$25.00

-0.6 (-2.34%)

VIAB

Viacom

$22.24

-0.37 (-1.64%)

CMCSA

Comcast

$45.49

-0.45 (-0.98%)

CMCSK

Comcast

$0.00

(0.00%)

LGF.A

Lionsgate

$8.50

-0.1 (-1.16%)

LGF.B

Lionsgate

$8.00

-0.07 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

MAS

Masco

$43.82

0.18 (0.41%)

13:45
10/18/19
10/18
13:45
10/18/19
13:45
Options
Masco call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

IGT

International Game

$13.15

-0.25 (-1.87%)

13:25
10/18/19
10/18
13:25
10/18/19
13:25
Options
International Game call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
10/18/19
10/18
13:25
10/18/19
13:25
General news
Wall Street is taking a hit on a couple of news items »

Wall Street is taking a…

13:25
10/18/19
10/18
13:25
10/18/19
13:25
Conference/Events
JPMorgan autos/auto parts analyst to hold an analyst/industry conference call »

Autos & Auto Parts…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
10/18/19
10/18
13:17
10/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
10/18/19
10/18
13:16
10/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGAL

Grupo Financiero

$12.45

-0.05 (-0.40%)

13:15
10/18/19
10/18
13:15
10/18/19
13:15
Options
Grupo Financiero put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWBO

Northwest Biotherapeutics

$0.00

(0.00%)

13:12
10/18/19
10/18
13:12
10/18/19
13:12
Syndicate
Breaking Syndicate news story on Northwest Biotherapeutics »

Northwest Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BA

Boeing

$355.77

-13.36 (-3.62%)

13:12
10/18/19
10/18
13:12
10/18/19
13:12
Periodicals
Boeing pilot said he 'lied' to FAA in texts to colleague, NY Times reports »

Mark Forkner, a Boeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

MAT

Mattel

$11.18

0.07 (0.63%)

13:06
10/18/19
10/18
13:06
10/18/19
13:06
Recommendations
Mattel analyst commentary  »

Jefferies sees increased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

13:05
10/18/19
10/18
13:05
10/18/19
13:05
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 10/18…

FEYE

FireEye

$15.06

-0.06 (-0.40%)

13:05
10/18/19
10/18
13:05
10/18/19
13:05
Options
FireEye call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

BHGE

Baker Hughes

$0.00

(0.00%)

13:03
10/18/19
10/18
13:03
10/18/19
13:03
Hot Stocks
Baker Hughes reports U.S. rig count down 5 to 851 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

MAT

Mattel

$11.26

0.15 (1.35%)

12:59
10/18/19
10/18
12:59
10/18/19
12:59
Periodicals
Study finds Fisher-Price Rock 'n Play 'dangerous and deadly,' CBS News says »

A study has found that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

NKE

Nike

$95.67

0.13 (0.14%)

12:55
10/18/19
10/18
12:55
10/18/19
12:55
Options
Nike put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.